Showing results (71-80 of 179) with videos related to
Sort By:
Pageof 18
Cancer Treatment and Research Communications|December 11, 2024
The prevalence and prognostic significance of Sarcopenia and Adipopenia in Pleural MesotheliomaAndrew C Kidd, Gordon W Cowell, Geoffrey A Martin, et al.Cancer Research|October 17, 2008
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAILSandra Van Schaeybroeck, Donal M Kelly, Joan Kyula, et al.Frontiers in Oncology|December 12, 2022
Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibitionGiulia Pinton, Zhuo Wang, Cecilia Balzano, et al.Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesotheliomaJasper H L T van Genugten, Daniel Faulkner, Jens C Hahne, et al.Oncotarget|October 15, 2013
The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasisCheryl McFarlane, Suzanne McFarlane, Ian Paul, et al.Biomaterials|August 31, 2011
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug deliveryFrancois Fay, Kirsty M McLaughlin, Donna M Small, et al.Journal of Cardiovascular Pharmacology|February 1, 1991
Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidaseA A Seymour, J A Norman, M M Asaad, et al.Journal of Cardiovascular Pharmacology|July 1, 1990
Renal and depressor effects of SQ 29,072, a neutral endopeptidase inhibitor, in conscious hypertensive ratsA A Seymour, J A Norman, M M Asaad, et al.International Journal of Cancer|August 8, 2007
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancerDean A Fennell, Jeremy P C Steele, Jonathan Shamash, et al.Cancer|December 6, 2006
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesotheliomaDean A Fennell, Jeremy P C Steele, Jonathan Shamash, et al.Pageof 18